Roche office high-rise: Construction of building shell starts

Basel, 09 May 2012

Roche holds foundation stone-laying ceremony for Building 1

Today Roche is holding the foundation stone-laying ceremony for Building 1, the company’s new office high-rise in Basel. The new building will enable Roche to relocate some 2,000 employees from offices across the city to its main site in Grenzacherstrasse. Shell construction will be completed by the end of 2014. Interior fit-out work will take place simultaneously, starting in 2013. Total capital expenditure on the project will amount to 550 million Swiss francs.

“The new office high-rise will provide workspace for people in research, development, production and marketing”, explained Roche CEO Severin Schwan. “Dialogue is the basis of all innovation. We are convinced that locating departments close to each other is crucial in ensuring that they work together successfully. That’s why we’ll be bringing most of the 2000-plus employees who currently work in offices all over the city back to our main Basel site.”

“This investment in our new main office building is a clear expression of Roche’s commitment to the Basel site”, said Site Head Matthias M. Baltisberger. “We are very happy with the way the building work is progressing, and would like to thank everyone concerned for the good working relationship.”

During the foundation stone-laying ceremony, a casket will be buried. As well as the plans of Building 1, its contents include a paper scroll listing the names of everyone who works at the Basel site.

Construction of the new building began in February 2011. Excavation work on the foundation pit was completed in April, and Building 1 will be ready for occupation in 2015.

About site development at Roche

Current site development at Roche Basel aims to bring together the global and corporate functions on the site area south of Grenzacherstrasse, while infrastructure-intensive research, development and production units will be located on the area north of the road. Apart from meeting operational requirements, Roche attaches top priority, as with all its new-build schemes, to upholding the high standards of industrial architecture for which it is renowned.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com

All trademarks used or mentioned are protected by law.